drugset / Trial / NCT03488524

Open Label Extension Study of AMX0035 in Patients With ALS

NCT03488524

NaSingle-groupOpen-labelTreatment

Summary

This extension study, in which all participants received active treatment (AMX0035), was designed to assess the longer-term safety and therapeutic potential of AMX0035 for participants who have completed the Main Study (AMX3500, also known as CENTAUR).

Timeline

Start
2018-03-29
Primary completion
2021-03-01
Completion
2021-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Phenylbutyrate Small molecule 3 g Oral
Subject Taurursodiol Small molecule 1 g Oral